Bone metabolism during long-term treatment with imatinib.
about
Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.Adverse skeletal effects of drugs - beyond Glucocorticoids.Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study.Bone morbidity in chronic myeloproliferative neoplasms.Imatinib and chronic myeloid leukemia: close to the bone.
P2860
Bone metabolism during long-term treatment with imatinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Bone metabolism during long-term treatment with imatinib.
@en
Bone metabolism during long-term treatment with imatinib.
@nl
type
label
Bone metabolism during long-term treatment with imatinib.
@en
Bone metabolism during long-term treatment with imatinib.
@nl
prefLabel
Bone metabolism during long-term treatment with imatinib.
@en
Bone metabolism during long-term treatment with imatinib.
@nl
P2093
P2860
P1433
P1476
Bone metabolism during long-term treatment with imatinib.
@en
P2093
Andrew Grey
Diana Wattie
Fran Porteous
Greg Gamble
Peter Browett
Susannah O'Sullivan
P2860
P304
P356
10.3109/10428194.2012.760734
P50
P577
2013-01-24T00:00:00Z